BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a generic pharmaceutical company, today announced the release of its latest product, Biolon OVD (Ophthalmic Viscosurgical Device). Amring is excited to offer this device to position itself in the growing ophthalmic market with the introduction of Biolon OVD.
Biolon OVD is a fermentation-based, sterile, optically clear, 1% (10mg/mL), sodium hyaluronate viscoelastic, provided in a sterile prefilled syringe. Biolon OVD has been used by cataract surgeons across the globe for over 25 years and Amring is bringing this product to surgeons in the United States.
Cataract surgeries are one of the most common surgical procedures in the country, with approximately 3.6 million performed each year in the United States. Biolon OVD offers a high-quality alternative OVD option for cataract surgeons. Biolon OVD provides surgeons with a full 1.0 mL of viscoelastic per syringe, (17% more viscoelastic per syringe, versus syringe volume fill of 0.85mL). Other key benefits of Biolon OVD include: “Easy-Prep” with a “Snap, Attach, Ready” tamper evident closure, Room Temperature excursions (up to one (1) month), and 25 years of NaHA manufacturing experience in a highly purified Non-Avian sourced viscoelastic.
With a focus on value and a dedication to quality, Amring has partnered with Bio-Technology General (Israel) Ltd. to produce Biolon OVD and partnered with Altacor to license the product in North America.
Biolon OVD is available via surgical distribution networks.
More information and Surgeon Evaluation Kits can be obtained by calling 1-844-AMRING1 (267-4641) or by visiting biolonusa.com.
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals is a privately-held generic pharmaceutical company active in global markets geared to supplying unique and specialized products. The company is part of the global Amring Pharmaceuticals business and is partnered with well-established global biopharmaceutical companies. Amring is uniquely positioned to leverage its partners’ expertise in bringing biotechnology derived medicines, as well as patient-friendly drug delivery systems, sterile manufacturing and other state-of-the art technologies to the marketplace.
Altacor is a specialist ophthalmology company marketing a portfolio of products in the fields of ocular surface disease and ophthalmic surgery. The company differentiates its development products primarily through formulation or reprofiling existing compounds with established clinical activity and systemic safety.
About Bio-Technology General (Israel) Ltd.
Bio-Technology General (BTG) is an integrated biopharmaceutical company founded in 1980; since July 2005, it has been part of the Swiss-based Ferring Group, a multinational pharmaceutical company operating worldwide. BTG is a pioneer in the development and manufacture of human health care products derived from genetic engineering and biotechnology processes, and has a successful track record of developing and registered biopharmaceuticals.
This press release contains forward-looking statements, including, without limitation, statements related to Amring's business developments and the implementation of Amring's strategic initiatives. Because these statements reflect Amring's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring's expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring's business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.